Tumorigenesis and the angiogenic switch

被引:2744
作者
Bergers, G
Benjamin, LE
机构
[1] Univ Calif San Francisco, Dept Neurol Surg, Brain Tumor Res Ctr, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
[3] Harvard Univ, Sch Med, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
关键词
D O I
10.1038/nrc1093
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It has become evident that we cannot understand tumour growth without considering components of the stromal microenvironment, such as the vasculature. At the same time, the tumour phenotype determines the nature of the tumour vasculature. Much research is now devoted to determining the impact of angiogenesis on tumour development and progression, and the reciprocal influences of tumour products on the microvasculature. A more detailed understanding of the complex parameters that govern the interactions between the tumour and vascular compartments will help to improve anti-angiogenic strategies-not only for cancer treatment, but also for preventing recurrence.
引用
收藏
页码:401 / 410
页数:10
相关论文
共 110 条
[51]   Cyclooxygenase-2 and prostate carcinogenesis [J].
Hussain, T ;
Gupta, S ;
Mukhtar, H .
CANCER LETTERS, 2003, 191 (02) :125-135
[52]   Cyclooxygenase-2:: a therapeutic target in angiogenesis [J].
Iñiguez, MA ;
Rodríguez, A ;
Volpert, OV ;
Fresno, M ;
Redondo, JM .
TRENDS IN MOLECULAR MEDICINE, 2003, 9 (02) :73-78
[53]   VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis [J].
Inoue, M ;
Hager, JH ;
Ferrara, N ;
Gerber, HP ;
Hanahan, D .
CANCER CELL, 2002, 1 (02) :193-202
[54]  
Joseph IBJK, 1996, CANCER RES, V56, P3404
[55]   Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth [J].
Kamphaus, GD ;
Colorado, PC ;
Panka, DJ ;
Hopfer, H ;
Ramchandran, R ;
Torre, A ;
Maeshima, Y ;
Mier, JW ;
Sukhatme, VP ;
Kalluri, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (02) :1209-1215
[56]   Clinical translation of angiogenesis inhibitors [J].
Kerbel, R ;
Folkman, J .
NATURE REVIEWS CANCER, 2002, 2 (10) :727-739
[57]   Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity [J].
Klement, G ;
Baruchel, S ;
Rak, J ;
Man, S ;
Clark, K ;
Hicklin, DJ ;
Bohlen, P ;
Kerbel, RS .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (08) :R15-R24
[58]   Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia [J].
Kwak, C ;
Jin, RJ ;
Lee, C ;
Park, MS ;
Lee, SE .
BJU INTERNATIONAL, 2002, 89 (03) :303-309
[59]  
Laderoute KR, 2000, CLIN CANCER RES, V6, P2941
[60]  
Laird AD, 2000, CANCER RES, V60, P4152